Literature DB >> 15362047

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection.

Georg M Lauer1, Eleanor Barnes, Michaela Lucas, Joerg Timm, Kei Ouchi, Arthur Y Kim, Cheryl L Day, Gregory K Robbins, Deborah R Casson, Markus Reiser, Geoffrey Dusheiko, Todd M Allen, Raymond T Chung, Bruce D Walker, Paul Klenerman.   

Abstract

BACKGROUND & AIMS: Cellular immune responses are thought to play a key role in the resolution of primary HCV infection. Although it has been consistently shown that CD4+ T-cell responses are maintained in those with spontaneous resolution but lost in those with persistent infection, the role of CD8+ T-cell responses remains controversial. Previous studies have largely focused on limited HLA alleles and predefined CD8+ T-cell epitopes, and, thus, comprehensive studies remain to be performed.
METHODS: To understand the composition of the immune response associated with spontaneous resolution, we comprehensively mapped CD8+ T-cell responses in 20 HLA-diverse persons with resolved HCV infection, using HCV peptides spanning the entire genome. We analyzed the magnitude, breadth, function, and phenotype using ELISpot, class-I tetramers, intracellular cytokine staining, and cytolytic assays. We studied in parallel HCV-specific responses and viral sequence variation in persistent infection.
RESULTS: Responses in individuals with resolved infection were strong and broad with robust proliferation in response to antigen. Responses in those persistently infected were rarely detected ex vivo and, when present, were narrowly directed and weak. However, they also proliferated in vitro. Dominant target epitopes differed among individuals in both cohorts, despite frequently shared HLA-alleles.
CONCLUSIONS: These data indicate that persisting, strong CD8+ T-cell responses are observed in the majority of persons with resolved HCV infection and provide support for strategies to boost CD8+ T-cell responses for the prevention or treatment of HCV infection but also highlight the diversity of responses that may need to be elicited to provide protection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362047     DOI: 10.1053/j.gastro.2004.06.015

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  112 in total

1.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected].

Authors:  Krystle A Lang Kuhs; Arielle A Ginsberg; Jian Yan; Roger W Wiseman; Amir S Khan; Niranjan Y Sardesai; David H O'Connor; David B Weiner
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

2.  Human leukocyte antigen B27 selects for rare escape mutations that significantly impair hepatitis C virus replication and require compensatory mutations.

Authors:  Christoph Neumann-Haefelin; Cesar Oniangue-Ndza; Thomas Kuntzen; Julia Schmidt; Katja Nitschke; John Sidney; Célia Caillet-Saguy; Marco Binder; Nadine Kersting; Michael W Kemper; Karen A Power; Susan Ingber; Laura L Reyor; Kelsey Hills-Evans; Arthur Y Kim; Georg M Lauer; Volker Lohmann; Alessandro Sette; Matthew R Henn; Stéphane Bressanelli; Robert Thimme; Todd M Allen
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

Review 3.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

4.  Cellular immune responses against persistent hepatitis C virus: gone but not forgotten.

Authors:  P Klenerman; N Semmo
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

5.  Cellular immune responses associated with occult hepatitis C virus infection of the liver.

Authors:  Juan A Quiroga; Silvia Llorente; Inmaculada Castillo; Elena Rodríguez-Iñigo; Margarita Pardo; Vicente Carreño
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

6.  Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Authors:  Silvana Gaudieri; Andri Rauch; Lawrence P Park; Elizabeth Freitas; Susan Herrmann; Gary Jeffrey; Wendy Cheng; Katja Pfafferott; Kiloshni Naidoo; Russell Chapman; Manuel Battegay; Rainer Weber; Amalio Telenti; Hansjakob Furrer; Ian James; Michaela Lucas; Simon A Mallal
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

7.  Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver.

Authors:  Bertram Bengsch; Hans Christian Spangenberg; Nadine Kersting; Christoph Neumann-Haefelin; Elisabeth Panther; Fritz von Weizsäcker; Hubert E Blum; Hanspeter Pircher; Robert Thimme
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells.

Authors:  Gamal Badr; Nathalie Bédard; Mohamed S Abdel-Hakeem; Lydie Trautmann; Bernard Willems; Jean-Pierre Villeneuve; Elias K Haddad; Rafick P Sékaly; Julie Bruneau; Naglaa H Shoukry
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution.

Authors:  Victoria Kasprowicz; Yu-Hoi Kang; Michaela Lucas; Julian Schulze zur Wiesch; Thomas Kuntzen; Vicki Fleming; Brian E Nolan; Steven Longworth; Andrew Berical; Bertram Bengsch; Robert Thimme; Lia Lewis-Ximenez; Todd M Allen; Arthur Y Kim; Paul Klenerman; Georg M Lauer
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Cell-mediated immune responses directed against hepatitis C virus (HCV) alternate reading frame protein (ARFP) are undetectable during acute infection.

Authors:  Christian Drouin; Stéphanie Lamarche; Julie Bruneau; Hugo Soudeyns; Naglaa H Shoukry
Journal:  J Clin Virol       Date:  2009-12-01       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.